Note

StoneX Group Inc. Announces Closing of $550 Million of Senior Secured Notes due 2031

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- StoneX Group Inc. (the “Company”; NASDAQ: SNEX), today announced the closing of its previously-announced offering of $550 million in aggregate principal amount of 7.875% Senior Secured Notes due 2031 (the “Notes”).

Key Points: 
  • NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- StoneX Group Inc. (the “Company”; NASDAQ: SNEX), today announced the closing of its previously-announced offering of $550 million in aggregate principal amount of 7.875% Senior Secured Notes due 2031 (the “Notes”).
  • The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured second lien basis by each of the Company’s existing and future subsidiaries that guarantees indebtedness under the Company’s senior secured revolving credit facility and certain other senior indebtedness.
  • The Notes and the related guarantees are secured on a second priority basis by liens on substantially all of the Company’s and the guarantors’ property and assets, subject to certain exceptions and permitted liens.
  • Any offers of the Notes and the related guarantees were made only by means of a private offering memorandum.

The RealReal Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024

SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The RealReal (Nasdaq: REAL)—the world’s largest online marketplace for authenticated, resale luxury goods—today reported financial results for its fourth quarter and full year ended December 31, 2023. Fourth quarter 2023 Net Loss was $22 million, compared to $39 million in the fourth quarter of 2022. Fourth quarter 2023 Adjusted EBITDA was positive $1.4 million, a $22 million improvement compared to the fourth quarter of 2022. Full year 2023 Net Loss was $168 million, compared to $196 million for full year 2022. Full year 2023 Adjusted EBITDA was $(55) million, compared to $(112) million for full year 2022.

Key Points: 
  • Fourth quarter 2023 Net Loss was $22 million, compared to $39 million in the fourth quarter of 2022.
  • Fourth quarter 2023 Adjusted EBITDA was positive $1.4 million, a $22 million improvement compared to the fourth quarter of 2022.
  • Full year 2023 Net Loss was $168 million, compared to $196 million for full year 2022.
  • “In the fourth quarter of 2023, The RealReal delivered positive Adjusted EBITDA and positive free cash flow.

ASP Isotopes Inc. Announces Signing of Purchase Agreement for Offering of Convertible Notes by Quantum Leap Energy

Retrieved on: 
Thursday, February 29, 2024

The offering of QLE Notes was oversubscribed and is expected to result in gross proceeds to QLE of greater than $20 million.

Key Points: 
  • The offering of QLE Notes was oversubscribed and is expected to result in gross proceeds to QLE of greater than $20 million.
  • The QLE Notes will mature on the fifth anniversary of the initial closing, unless converted in accordance with their terms prior to such date.
  • The closing of the QLE Notes offering is subject to the fulfillment or waiver of certain conditions contained in the purchase agreement.
  • No offering of the QLE Notes or the common equity securities of QLE deliverable upon conversion of the QLE Notes (if any) was made into the United States or to U.S. persons.

iQIYI Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

The monthly average revenue per membership (ARM5) for the fourth quarter was RMB15.98, compared to RMB14.17 for the same period in 2022 and RMB15.54 for the third quarter in 2023, increasing 13% year over year.

Key Points: 
  • The monthly average revenue per membership (ARM5) for the fourth quarter was RMB15.98, compared to RMB14.17 for the same period in 2022 and RMB15.54 for the third quarter in 2023, increasing 13% year over year.
  • Diluted net income attributable to iQIYI per ADS was RMB0.48 (US$0.07) for the fourth quarter of 2023, compared to diluted net income attributable to iQIYI per ADS of RMB0.35 in the same period of 2022.
  • Net income attributable to iQIYI was RMB1.9 billion (US$271.2 million), compared to net loss attributable to iQIYI of RMB136.2 million in 2022.
  • It will automatically direct you to the registration page of " iQIYI Fourth Quarter and Fiscal Year 2023 Earnings Conference Call", where you may fill in your details for RSVP.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Wednesday, February 28, 2024

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Tuesday, February 27, 2024

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

Cumulus Media Announces Exchange Offer and Consent Solicitation Relating to 6.750% Senior Secured First-Lien Notes due 2026

Retrieved on: 
Tuesday, February 27, 2024

In conjunction with the Exchange Offer, the Issuer is also soliciting consents (the “Consent Solicitation”) to amend certain provisions in the Old Notes Indenture (the “Proposed Amendments”).

Key Points: 
  • In conjunction with the Exchange Offer, the Issuer is also soliciting consents (the “Consent Solicitation”) to amend certain provisions in the Old Notes Indenture (the “Proposed Amendments”).
  • Holders may not tender their Old Notes pursuant to the Exchange Offer without delivering a consent with respect to such Old Notes tendered pursuant to the Consent Solicitation, and holders may not deliver a consent pursuant to the Consent Solicitation without tendering the related Old Notes pursuant to the Exchange Offer.
  • The consummation of the Term Loan Exchange Offer is not conditioned on the consummation of the Exchange Offer.
  • King & Co., Inc. will act as the Information Agent and the Exchange Agent for the Exchange Offer.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.

Key Points: 
  • Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.
  • R&D expenses were $69.3 million for the fourth quarter of 2023, compared to $99.4 million for the fourth quarter of 2023.
  • G&A expenses were $141.7 million for the fourth quarter of 2023, compared to $84.4 million for the fourth quarter of 2022.
  • Apellis will host a conference call and webcast to discuss its fourth quarter and year end 2023 financial results and business highlights today, February 27, 2024, at 8:30 a.m.

Eightco announces early repayment of debt, private placement and certain changes at the parent company level

Retrieved on: 
Monday, February 26, 2024

In addition to lowering debt levels, the repayment of the Hudson Bay Note now gives the Company the ability to attract efficient capital to grow its subsidiary, Forever 8 Fund, LLC (“Forever 8”).

Key Points: 
  • In addition to lowering debt levels, the repayment of the Hudson Bay Note now gives the Company the ability to attract efficient capital to grow its subsidiary, Forever 8 Fund, LLC (“Forever 8”).
  • The Company also announced the appointment and departures of certain officers, as well as the issuance of common stock to reduce and satisfy certain outstanding obligations as related to consultants, former and current employees and directors of the company.
  • The Company continues to reduce ongoing costs at the parent company level so it can focus its resources on delivering growth via its main subsidiary Forever 8.
  • Accordingly, the shares of common stock issued in the Private Placement and the Notes may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

Sunrun Inc. Announces Pricing of Offering of $475 Million of Convertible Senior Notes

Retrieved on: 
Friday, February 23, 2024

The sale of the notes is expected to close on February 27, 2024, subject to customary closing conditions.

Key Points: 
  • The sale of the notes is expected to close on February 27, 2024, subject to customary closing conditions.
  • The notes will be senior, unsecured obligations of Sunrun.
  • The notes will be convertible into cash, shares of Sunrun’s common stock or a combination of cash and shares of Sunrun’s common stock, at Sunrun’s election.
  • If the initial purchasers exercise their option to purchase additional notes, Sunrun expects to enter into additional capped call transactions with the option counterparties.